ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/breast/metastatic/her2-low
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Breast / Breast - Metastatic / HER2-low
7
trial(s) found.
NCT07300943
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of CLIO-8221 in Patients With Advanced Solid Tumors (
CLIO-8221-001
)
anti-ERBB2 antibody-drug conjugate,topoisomerase/ATR inhibitor-payload
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06827236
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer (
BNT323-03
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
bispecific PD-L1/VEGFA antibody
Breast cancer
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5000 - Adelaide - Cancer Research SA
NCT05950945
Advanced
Phase 3
Recruiting
A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-
HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low
or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15) (
DS8201-0001-CIS-MA
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Breast cancer
NSW
2060 - North Sydney - Mater Hospital
VIC
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus
SA
5000 - South Australia - GenesisCare St Andrews Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05872295
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors (
IKS014-01
)
anti-ERBB2 antibody-drug conjugate,MMAF-payload
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05636215
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicenter, Open-label Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors (
CIBI354A101
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Biliary tract cancer
Breast cancer
Colorectal cancer
Gastric cancer
Gynaecological cancer
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
NCT05356741
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of VIR-5818 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (
VIR-5818-V101
)
anti-PD-1 monoclonal antibody
bispecific T-cell engager,ERBB2-targeting
HER2-expressing solid tumour
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT03424005
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (
Morpheus-panBC
)
AKT inhibitor
Abemaciclib
Atezolizumab
Atirmociclib
Bevacizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK4 selective inhibitor
CDK6 inhibitor
Capecitabine
Carboplatin
ER degrader
Eribulin
Fulvestrant
Gemcitabine
Giredestrant
Inavolisib
Ipatasertib
Ladiratuzumab Vedotin
Letrozole
Metformin
Nab-paclitaxel
PI3K alpha inhibitor
Palbociclib
Ribociclib
Sacituzumab Govitecan
Selicrelumab
Tocilizumab
Trastuzumab Deruxtecan
agnostic antibody,CD40-targeting
anti-CD40 agonistic antibody
anti-ERBB2 antibody-drug conjugate
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-IL-6 monoclonal antibody
anti-LIV1 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
antimetabolite
aromatase inhibitor
biguanide antihyperglycaemic agent
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CD40-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK4 selective-targeting
cancer therapy,CDK6-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,IL-6-targeting
cancer therapy,LIV1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,oestrogen axis-targeting
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CD40-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LIV1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGF-targeting
macrocyclic ketone analogue
oestrogen receptor-targeting therapy
pan-AKT inhibitor
platinum-based antineoplastic agent
selective estrogen receptor degrader
taxane
Breast cancer
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
WA
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (7)
Recruitment Country and State
VIC (7)
NSW (5)
WA (4)
QLD (2)
SA (2)
NZ (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (5)
Phase 3 (1)
Trial Type
Advanced (7)
Cancer Therapy Class
ERBB2
100%
PD-1/PD-L1
43%
PD-L1
29%
ATR
14%
VEGFA
14%
PD-1
14%
AKT
14%
CD40
14%
CDK4
14%
CDK4 selective
14%
CDK6
14%
ER
14%
IL-6
14%
LIV1
14%
PI3Kalpha
14%
Trop2
14%
VEGF
14%
oestrogen axis
14%
Facility
2031 - Randwick - Scientia Clinical Research Ltd (3)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
6009 - Nedlands - Linear Clinical Research (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
5000 - Adelaide - Cancer Research SA (1)
2060 - North Sydney - Mater Hospital (1)
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
2109 - North Ryde - Macquarie University Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
3168 - Clayton - Monash Medical Centre (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
Cancer Type
Cancer
Solid tumour
Breast cancer
Gastric cancer
Gastroesophageal cancer
Gastrointestinal cancer
Upper gastrointestinal cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Thoracic cancer
Biliary tract cancer
Colorectal cancer
Gynaecological cancer
Hepatobiliary cancer
Lower gastrointestinal cancer
Pancreatobiliary cancer
HER2-expressing solid tumour
HER2-positive solid tumour
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy